Weight management guide
Semaglutide
Semaglutide is a GLP-1 medication used in several prescription products. Patients often ask about it for appetite, weight-management, blood-sugar, and metabolic-health goals.
Overview
What Semaglutide is
Semaglutide works with the GLP-1 pathway involved in appetite, digestion, and blood-sugar regulation. Wegovy, Ozempic, and Rybelsus contain semaglutide in different formulations used for different clinical goals.
Potential benefits and patient goals
- Medical weight-management goals
- Appetite and fullness questions
- Understanding Wegovy, Ozempic, and Rybelsus
Your next step
Build a plan around your goals
A free virtual consultation gives you a direct way to connect your goals with the potential benefits of Semaglutide, ask questions, and explore a personalized next step. If an in-person examination or testing would strengthen the plan, the care team will make that process clear.
Begin with a free virtual consultation to discuss your goals, questions, and the semaglutide options that may fit your care plan.
Book a free virtual consultationRelated care
Explore more treatment options
Questions
Common questions about Semaglutide
What is semaglutide?
Semaglutide is a GLP-1 medication used in prescription products for weight management or type 2 diabetes, depending on the specific product.
How are Wegovy, Ozempic, and Rybelsus related?
All three contain semaglutide, but they have different product names, formulations, and clinical uses.
Why do patients ask about semaglutide?
Patients commonly ask about appetite, fullness, weight-management, blood-sugar, and broader metabolic-health goals.
Can I start with a free virtual consultation?
Yes. A virtual consultation gives you time to discuss your goals, medical history, previous approaches, and questions about semaglutide.
Ready to explore your options?
Take the next step toward your goals
Meet with the Florida Regenerative care team to explore potential benefits, compare treatment options, and build a plan around what you want to improve.